# Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease

> **NCT02225132** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 10 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Hydroxyurea

## Key facts

- **NCT ID:** NCT02225132
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-23
- **Primary completion:** 2018-05-24
- **Final completion:** 2018-05-24
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02225132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02225132, "Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02225132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*